Ambroxol hydrochloride
important information for the patient.
This medicine should always be taken exactly as described in the patient leaflet or as advised by a doctor or pharmacist.
Deflegmin KIDS syrup is a mucolytic medicine containing ambroxol hydrochloride. It increases the secretion of mucus in the airways and improves its transport, making it easier to cough up and relieving cough.
Deflegmin KIDS is used in acute and chronic lung and bronchial diseases with difficulty in coughing up viscous secretions from the airways.
Before starting to take Deflegmin KIDS, the patient should discuss it with their doctor or pharmacist:
Severe skin reactions associated with the use of ambroxol hydrochloride have been reported. If a rash occurs (including changes in mucous membranes, such as the mouth, throat, nose, eyes, genitals), the patient should stop taking Deflegmin KIDS and contact their doctor immediately.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
Deflegmin KIDS syrup should be taken after meals.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medicine.
Ambroxol hydrochloride is not recommended during pregnancy, especially in the first trimester.
Ambroxol passes into breast milk. Deflegmin KIDS syrup is not recommended during breastfeeding.
The effect of the medicine on human fertility has not been studied.
Animal studies have not shown any harmful effects of ambroxol on fertility.
There is no evidence that the medicine affects the ability to drive or use machines.
No studies have been conducted on the effect of Deflegmin KIDS syrup on the ability to drive or use machines.
The medicine contains 1250 mg of sorbitol in the form of sorbitol solution per 2.5 ml of syrup, which corresponds to 2500 mg of sorbitol/5 ml of syrup or 5000 mg of sorbitol/10 ml of syrup.
Sorbitol is a source of fructose. If the patient (or their child) has previously been diagnosed with intolerance to some sugars or has a rare genetic disorder, hereditary fructose intolerance, in which the patient's body does not break down fructose, they should consult their doctor before taking the medicine or giving it to their child.
Sorbitol may cause gastrointestinal discomfort and have a mild laxative effect.
The medicine contains 42.4 mg of propylene glycol per 2.5 ml of syrup, which corresponds to 169.6 mg/10 ml of syrup.
The medicine contains 5 mg of sodium benzoate per 2.5 ml of syrup, which corresponds to 20 mg/10 ml of syrup.
The medicine contains less than 1 mmol (23 mg) of sodium per 10 ml of syrup, which means the medicine is considered "sodium-free".
Deflegmin KIDS syrup does not contain sugar.
This medicine should always be taken exactly as described in the patient leaflet or as advised by a doctor or pharmacist. If in doubt, the patient should consult their doctor or pharmacist.
The usual dose of Deflegmin KIDS syrup:
for adults and children over 12 years of age:
initially, for 2 to 3 days, 10 ml of syrup 3 times a day, then the dose should be reduced to 10 ml of syrup 2 times a day;
for children from 6 to 12 years of age:
5 ml of syrup 2 to 3 times a day;
for children from 2 to 6 years of age:
2.5 ml of syrup 3 times a day;
for children from 1 to 2 years of age:
2.5 ml of syrup 2 times a day.
If there is no improvement or the patient feels worse after 4 to 5 days of taking the medicine, they should contact their doctor.
No cases of overdose have been reported. However, if symptoms such as nausea, excessive fatigue, or excessive mucus production occur, the patient should contact their doctor immediately.
If a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next dose, the missed dose should be skipped. A double dose should not be taken to make up for a missed dose.
Stopping Deflegmin KIDS syrup does not cause any adverse effects, except for the possibility of worsening symptoms of the disease for which it is being taken.
If the patient has any further doubts about taking this medicine, they should consult their doctor or pharmacist.
Like all medicines, Deflegmin KIDS syrup can cause side effects, although not everybody gets them.
The frequency of the above side effects is unknown (cannot be estimated from the available data).
In addition, the following side effects may occur:
Common side effects(may affect up to 1 in 10 people):
Uncommon side effects(may affect up to 1 in 100 people):
Rare side effects(may affect up to 1 in 1000 people):
Side effects with unknown frequency(frequency cannot be estimated from the available data):
If the patient experiences any side effects, including any side effects not listed in the leaflet, they should inform their doctor or pharmacist. Side effects can be reported directly to the Department of Medicinal Product Monitoring, Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych:
Al. Jerozolimskie 181 C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309,
website: https://smz.ezdrowie.gov.pl.
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of the medicine.
Store in a temperature below 25°C. Store in the original packaging. Protect from light.
The medicine should be kept out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging after "Expiry date". The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
A brown glass bottle containing 120 ml or 150 ml of syrup, closed with a child-resistant PP cap and a tamper-evident seal. A polypropylene measuring cup is attached to the bottle. The outer packaging is a cardboard box.
Bausch Health Ireland Limited
3013 Lake Drive
Citywest Business Campus
Dublin 24, D24PPT3
Ireland
ICN Polfa Rzeszów S.A.
ul. Przemysłowa 2
35-959 Rzeszów
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.